---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000597"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:07:51.958288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reaffirms FY2022 net loss guidance of $245M–$265M

## Summary
- Net loss expected to be between $245M and $265M for the year ended December 31, 2022.
- Includes estimated non-cash stock-based compensation of approximately $30M to $35M.
- Company also posted a corporate presentation on January 10, 2023, covering its R&D pipeline.

## SEC filing metadata
- accession: 0000950170-23-000597
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/rvmd-20230110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000597
- JSON: https://secwatch.observer/filing/0000950170-23-000597.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000597.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported the year ended December 31, 2022 results: net income between $245 million and $265 million. Guidance reaffirmed.
  - Period: the year ended December 31, 2022
  - Net income: between $245 million and $265 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: On January 10, 2023, Revolution Medicines, Inc. (the “Company”) confirmed to investors that it continues to expect that its net loss for the year ended December 31, 2022 to be between $245 million and $265 million, which includes estimated non-cash stock-based compensation expense of approximately $30 million to $35 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.